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REKABENTUK SECARA RASIONAL DAN SINTESIS 
PERENCAT UNTUK ENZIM NEURAMINIDASE H1N1 DAN 
PROTEASE DENGGI 
 
ABSTRAK 
 
Influenza dan denggi adalah dua daripada penyakit berjangkit yang 
disebabkan oleh virus. Rintangan virus terhadap ubat influenza komersial dan 
ketiadaan ubat untuk merencat virus denggi menggalakkan usaha untuk mencari 
perencat virus yang berpotensi. Setakat ini, enzim neuraminidase H1N1 ialah satu 
daripada sasaran utama dalam pencarian perencat influenza A manakala enzim 
protease NS2B-NS3 DENV2 pula merupakan sasaran utama dalam penemuan ubat 
denggi. Kajian sebelum ini mendapati bahawa asid ferulik yang dipencilkan daripada 
kulit buah manggis dapat merencat aktiviti neuraminidase H1N1 dengan nilai IC50 = 
200 M. Struktur aromatiknya yang sederhana menarik perhatian untuk 
dikembangkan sebagai perencat neuraminidase H1N1. Sebanyak 20 terbitan asid 
ferulik telah pun direkabentuk dan disintesis. Kajian asai atas sebatian tersebut 
menunjukkan nilai IC50 daripada 50 sehingga > 1000 M. Rekabentuk hubungan 
kuantitatif struktur dan aktiviti menggunakan kaedah Multiple Linear Regression 
dilaksanakan untuk menghasilkan model yang menentukan hubungan positif 
daripada penderma dan penerima ikatan hidrogen dengan keputusan statistik yang 
baik (r
2
 = 0.758; r
2
 (adj) = 1.185; Least-squared error = 0.189). Dua model lagi 
direkabentuk berasaskan kajian hubungan kuantitatif struktur-aktiviti ini dan ianya 
diramalkan mempunyai IC50 lebih rendah daripada sebatian sebelumnya. Kajian 
sebelum ini mengenai penskrinan virtual daripada pangkalan data Institut Kanser 
Nasional terhadap protease NS2B-NS3 DENV2 menyarankan thioguanine sebagai 
perencat protease ini. Langkah penyelidikan yang sama juga dilaksanakan kepada 
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protease ini, menunjukkan nilai IC50 daripada 28 sehingga > 1000 M. Kajian 
hubungan kuantitatif struktur-aktiviti pula dilaksanakan menggunakan kaedah 
Genetic Function Approximation dengan Linear terpilih sebagai model terbaik 
berasaskan keputusan statistik ((r
2
 = 0.921; r
2
 (adj) = 0.884; r
2
 (pred) = 0.820; RMS 
residual errors = 0.258; Friedman L.O.F = 0.141 and S.O.R p-value = 1.919e
-006
). 
Model ini menentukan koefisien pembahagi sebagai deskriptor positif untuk 
rekabentuk seterusnya. Sebanyak empat ligan baru direkabentuk, disintesis dan 
ditentukan aktivitinya terhadap protease denggi. IC50 yang diramalkan dan 
ditentukan melalui aktiviti in vitro adalah saling setuju. Kesimpulannya, kaedah 
pemodelan in silico dalam kajian ini telah berjaya menunjukkan konsep 
merekabentuk perencat enzim secara rasional.  
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RATIONAL DESIGN AND SYNTHESIS OF INHIBITORS FOR 
H1N1 NEURAMINIDASE AND DENGUE PROTEASE ENZYME 
 
ABSTRACT 
 
Influenza and dengue are two of infectious diseases which caused by viruses. 
The viral resistances towards commercial anti-influenza as well as no drug available 
to combat dengue infection have prompted the search for potential inhibitors. 
Currently, H1N1 neuraminidase is one of the major targets in searching for inhibitor 
of influenza A as well as DENV2 NS2B-NS3 protease in dengue drug discovery. In a 
previous study, ferulic acid from G. mangostana pericarps has been isolated and 
showed an inhibition against H1N1 neuraminidase in vitro with IC50 = 200 M. Its 
simple aromatic structure was attractive to be developed as H1N1 neuraminidase 
inhibitor. Twenty ferulic acid derivatives were designed in silico and synthesised, 
respectively. The in vitro assay showed the inhibitory activity with IC50 from 50 to 
>1000 M. The Quantitative Structure-Activity Relationship (QSAR) modelling 
using Multiple Linear Regression was then carried out to produce the model defining 
a positive correlation of number of hydrogen bond donor as well as hydrogen bond 
acceptor with a good statistical results (r
2
 = 0.758; r
2
 (adj) = 1.185; Least-squared 
error = 0.189). Two further models were designed based on this QSAR equation and 
they were predicted to have lower IC50 values. On the other hands, previous study on 
virtual screening of National Cancer Institute database against DENV2 NS2B-NS3 
protease suggested thioguanine as a potential inhibitor for the enzyme. The same 
approach carried out on DENV2 protease inhibitor design demonstrated the 
inhibitors possessing IC50 in the range of 28 to >1000 µM. QSAR models were also 
generated using Genetic Function Approximation selecting a Linear model as the 
best QSAR equation upon statistical results (r
2
 = 0.921; r
2
 (adj) = 0.884; r
2
 (pred) = 
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0.820; RMS residual errors = 0.258; Friedman L.O.F = 0.141 and S.O.R p-value = 
1.919e
-006
). The model defined partition coefficient as the positive descriptors for 
further design. Four more ligands were then modeled, synthesised and tested their 
activity in vitro. The results showed a good agreement between its predicted and 
experimental IC50. In general, the in silico modelling used in this study successfully 
proved the concept of the rational enzyme inhibitor design. 
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CHAPTER ONE 
INTRODUCTION 
 
 
1.1 Statement of the Problem 
In recent years, world is threatened with the emergence of pandemic and 
endemic infections of viruses such as influenza A and dengue.  The news of highly 
pathogenic influenza (H5N1) transmission from birds to human that resulted in 53 
deaths in Vietnam, Cambodia and Thailand shocked the world in 2005 (WHO, 
2005). More deaths were reported in the subsequent years and the threat of H5N1 
now being compounded by the emergence of H1N1 pandemic in 2009. The World 
Health Organization (WHO) confirmed that the  pandemic was spread to over 220 
countries with more than 39 million cases and 15,417 deaths worldwide (see Figure 
1.1) (CDC, 2010a; Fajardo-Dolci et al., 2010). Compared to H5N1 avian influenza 
which emerged in 2005, H1N1 swine virus is less virulent but it is more prevalent 
than that of avian influenza (Salaam-Blyther, 2009).  
 
Figure 1.1 The death number of pandemic H1N1 influenza 2009 (CDC, 2010a). 
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Four years later in February 2013, a rare H7N9 subtype of avian influenza 
was isolated for the first time from the patient with pneumonia and acute respiratory 
distress syndrome in China. The infection showed alarming mortality rate (28% as of 
May 2013). Although H7N9 subtype is considered a low pathogen, the possibility of 
this subtype becomes resistant towards either vaccine or drug should be anticipated 
(Baranovich, 2013; Chen et al., 2013). 
 
Vaccines are available to prevent the infection of influenza. However, the 
existing vaccines have been mostly ineffective due to the emergence of rapidly 
variable mutation (Kim et al., 1999; Zhang et al., 2008a). Thus, the development of 
effective and safe anti-influenza becomes an urgent need (Gong et al., 2007; Zhang 
et al., 2008b). 
 
Historically, the adamantane-based M2 ion channel protein inhibitors 
(amantadine and rimantadine) were the first drugs available for the treatment of 
influenza. Such drugs had only been useful in the treatment of Influenza A infection 
due to the fact that only the A strain of the virus has M2 ion channel protein (von 
Itzstein, 2007). The drugs inhibit the virus replication by blocking this ion channel 
via binding at the allosteric site which triggers a conformational change in the pore 
region. This action causes interfering proton transfer through the ion channel across 
the membrane of the virus or endosome. Therefore, the virus is unable to penetrate 
the host cell of membrane and the replication being stopped (Sandrock, 2010; 
Tisdale, 2009). Several toxic effects (CNS toxicity can manifest dizziness, 
nervousness and insomnia and also gastrointestinal effect such as nausea, 
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constipation and lost of appetite) have been reported along with rapid emergence of 
drug-resistant variants. Studies between 1994 and 2005 showed the increase of 
worldwide amantadine and rimantadine-resistance from 0.4% to 12.3%. Thus, the 
use of these drugs have been discouraged (Moscona, 2008).  
 
Due to those disadvantages of M2 ion channel inhibitors, there was a shift to 
drug design targeting the other two surface glycoproteins; hemagglutinin (HA) and 
neuraminidase (NA), which are expressed by both influenza A and B. The HA plays 
as the receptor-binding and membrane fusion glycoprotein whilst the NA has a role 
as a receptor-destroying enzyme (An et al., 2009). So far, no HA inhibitors have 
been clinically approved for influenza treatment (Meshram and Jungle, 2009). 
 
Neuraminidase (NA), also known as sialidase, is the major surface 
glycoprotein that shows an important role in the viral replication, thus, has become 
an attractive target for anti-influenza drug.  Zanamivir and oseltamivir are two 
examples of drugs that are effective for either A or B types of neuraminidase. Studies 
on NA active site and Structure-Activity Relationships (SARs) of published NA 
inhibitors disclose that the relative positions of the substituents (carboxylate, 
glycerol, acetamido, and hydroxyl) of the central ring mainly determine inhibition of 
the NA (Zhang et al., 2008b).  
 
Although zanamavir is highly effective, its inhalational delivery (D'Souza et 
al., 2009; Hammad and Taha, 2009; Sun et al., 2010) is not very attractive as oral 
delivery (via capsule/tablet) is much preferred. Oseltamivir overcomes this 
limitation, but the production cost is quite expensive as it relies on the expensive 
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starting material shikimic acid (Chand et al., 1997). Although there have been a lot 
of efforts to discover new NA inhibitors with various scaffold, including aromatic 
(Chand et al., 1997; Luo et al., 1997), dihydropyrane (Taylor et al., 1998), 
cyclopentene (Babu et al., 2009), cyclohexene (Lew et al., 2000) and pyrrolidine 
(Zhang et al., 2008b), the currently circulating clinical H274Y H1N1 mutant is quite 
resistant to oseltamivir (Yen et al., 2006). Therefore, there is a need for new drugs 
that are cheaper and more effective against the influenza virus.  
 
Next to another infectious disease, dengue has become a major disease 
burden for the South East Asian countries. Although the scale of dengue infection 
has not reached pandemic proportion, WHO currently estimates that there may be 50 
million dengue infections worldwide every year (Murray et al., 2013), with the 
infection endemic in South East Asian Regions. During 2008, in Indonesia, there 
were 17,604 cases reported and 10,000 to 12,000 of them concentrated over East and 
Central Java (WHO, 2014a). Furthermore, it was reported that in India, Indonesia, 
Sri Lanka and Thailand, the epidemic season started up to 4 weeks earlier than 
normal, in part due to the heavy rainy season in 2010. In the same year, Vietnam has 
occurrence rates 10 times greater than in 2009 (CDC, 2010). In Malaysia itself, this 
deadly disease had killed 107 people in 2005 and 102 people in 2004 (Chen et al., 
2006). In 2014, Bernama reported that dengue fever striked 17 deaths and 9,453 
cases during January up to 2 February 2014, an increase over 100% of previous year 
(Bernama, 2014). It was reported that the case increased up close to 90,000 cases in 
December 2014. Figure 1.2 shows the dengue cases statistic in Malaysia from 1995-
2014 ("Development of dengue vaccine: status sreview and future considerations," 
2014). As of February 2015, the cases reached up to 59% more as compared to the 
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previous year, with 15,039 cases and 44 deaths as reported by Malaysian Department 
of Health (WHO, 2015).  
 
Figure 1.2 The dengue case statistic in Malaysia from 1995-2014 ("Development of 
dengue vaccine: status sreview and future considerations," 2014). 
 
 
Dengue virus carries a positive single strand RNA in its genome. 
Serologically, this virus is divided into four serotypes, i.e. DENV1, DENV2, DENV3 
and DENV4 (Jitendra and Vinay, 2011). Among those serotypes, DENV2 is the most 
prevalent type in dengue epidemic, especially in the South East Asian region. The 
virus genome is encoded by three structural proteins (C, prM, E) as well as seven 
non-structural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B and NS5) 
(Chambers et al., 1990; Henchal and Putnak, 1990). Understanding of the virus life 
cycle promotes the clearer key targets of gene/protein in the replication of the virus, 
thus, is important in a drug design study. Currently, the serine protease of dengue 
virus has been a major target in dengue drug discovery (Luo et al., 2008; Mueller et 
al., 2008).   
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Presently, available vaccines e.g. life recombinant, DNA and subunit vaccine 
are limited by their ability to protect the body system from the viral infection on one 
serotype only, e.g. if the vaccine is sensitive against DENV1 only, thus the patient is 
still exposed to the dangers of being infected by other serotypes (DENV2-4). 
Therefore, the discovery of antiviral drug is of utmost concern in the treatment of 
dengue and its related diseases (Nair et al., 2009; Tambunan et al., 2011). Up to now, 
there is no established antiviral drug able to inhibit the dengue virus replication. 
There are only symptomatic treatment administered to the dengue patient to relieve 
the symptoms such as analgesic-antipyretic for fever and blood transfusion to recover 
the thrombolytic level in hemorrhagic patient (Kumar et al., 2012; Zhou et al., 2008). 
One of antiviral drugs, ribavirin, successfully inhibited the virus replication in vitro 
but it is limited in in vivo study due to the fact that the sugar moiety of this 
compound contributes to its poor bioavaibility during oral administration (Sampath 
and Padmanabhan, 2009; Takhampunya et al., 2006).  
 
NS3 protease (NS3pro) is a trypsin like serine protease which plays a role in a 
post-translation from the genome to its proteins as well as its maturation. This 
enzyme has a catalytic triad made up by His51, Asp75 and Ser135 and enhanced by 
another non-structural protein named NS2B as an enzyme cofactor (Frimayanti et al., 
2011/2012; Yin et al., 2006b; Yin et al., 2006a). This cofactor activity is due to its 
hydrophilic region which is responsible for holding and promoting the activation of 
NS3 while the hydrophobic part playing around the membrane association upon the 
cleavage process (Chanprapaph et al., 2005; Kee et al., 2007; Niyomrattanakit et al., 
2004; Steuer et al., 2009).  
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In most cases, the discovery of dengue antivirus by targeting NS2B-NS3pro 
activity was based on the non-prime substrates which were identified by profiling 
dengue virus using tetrapeptides (Frecer and Miertus, 2010; Yang et al., 2011). This 
peptidomimetic compound is able to inhibit the enzyme activity in a nanomolar 
concentration; however it is devoid of drug-like structure which can create a problem 
in physicochemical stability either during pharmaceutical preparation or in further 
pharmacokinetic step. As such, no peptidomimetic compound has been clinically 
used as dengue antivirus (Katzenmeier, 2004; Steuer et al., 2011).  
 
Within the last decade, the discovery of NS2B-NS3pro inhibitor have been 
made possible by small molecules design (Kiat et al., 2006; Sidique et al., 2009; 
Tomlinson and Watowich, 2011), assisted by Computer Aided Drug Design 
(CADD). These virtual experiments are very helpful to avoid the trials and errors 
when the tested compound examined its activity in vitro as well as in vivo (Acharya 
et al., 2011; Korb et al., 2009; Tang and Marshall, 2011). There are various methods 
such as structure based drug design (docking and molecular dynamics) and ligand 
based drug designs (pharmacophore and quantitative structure-activity relationship 
(QSAR)). 
 
To date, there is no effective vaccine or antiviral drug available to protect 
against dengue diseases (Nair et al., 2009; Tambunan et al., 2011). Thus, as mortality 
and economic burden of this disease are quite high, major effort must be put in 
developing effective antiviral for the treatment against dengue. 
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Recently, a current unpublished study from Pharmaceutical Design and 
Simulation Laboratory, School of Pharmaceutical Sciences, USM, found that ferulic 
acid which was isolated from Garcinia mangostana pericarps showed a reasonable 
inhibition toward H1N1 neuraminidase with IC50 = 200 µM. Although this activity is 
still far away from the commercial drug (oseltamivir, Ki =  3.78 nM) but ferulic acid 
structure can be used as a scaffold for NA inhibitor. Looking at the structure of 
ferulic acid, there are three functional groups identified probably contributing to 
H1N1 neuraminidase inhibition, i.e. carboxylic acid, hydroxyl, and methoxy groups. 
Furthermore, the ring system of aromatic compound is more planar than shikimic 
acid derivatives which showed bound to the NA active site and had high anti-
neuraminidase activity (Chand et al., 1997). Ferulic acid has a highly correlated 
structure with vanillin (see Figure 1.3). Ferulic acid can be prepared synthetically by 
reacting vanillin and malonic acid; and vice versa, vanillin can be produced by 
hydrolyzing ferulic acid at a certain condition. 
OH
O
HO
O
CH3
Ferulic Acid
H
HO
O
CH3
O
Vanillin  
Figure 1.3 The structure of ferulic acid and vanillin. 
 
On the other hand, also unpublished previous works from Pharmaceutical 
Design and Simulation (PhDs) laboratory, USM, found four National Cancer 
Institute (NCI) compounds possessed bioactivity in vitro against DENV2 NS2B-
NS3pro from their virtual screening. Those four NCI compounds showed some 
hydrogen bond interactions to amino acid residues which are important for DENV2 
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NS2B-NS3pro activities. The docking results corresponded well with the in vitro 
study. These four compounds, however are not typically classified as 
peptidomimetic, therefore, there is an opportunity to develop small molecules to be 
the lead compound of dengue antivirus. Among those NCI compounds, the 
diversity0713 (see Figure 1.4) which has a thioguanine scaffold is considered 
chemically accessible in term of synthetic route as well as the availability of starting 
materials.  
N
N
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N
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SH
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Figure 1.4 The structure of diversity0713 (www.pubchem.com) and thioguanine. 
 
1.2 Objectives 
The goal of this study is to discover novel neuraminidase and dengue antivirus. 
Specifically the objectives are: 
1. To model and design a series of H1N1 NA and DENV2 NS2B-NS3pro 
inhibitors bearing ferulic acid and thioguanine scaffold respectively, using in 
silico methods. 
2. To synthesise the designed H1N1 NA and DENV2 NS2B-NS3pro inhibitors. 
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3. To evaluate the in vitro activities of the synthetic compounds (H1N1 NA and  
DENV2 NS2B-NS3pro inhibitors) against H1N1 NA and DENV2 NS2B-
NS3pro, respectively. 
4. To study the quantitative structure-activity relationship (QSAR) of the 
synthetic compounds, ferulic acid and thioguanine derivaties as the H1N1 NA 
and DENV2 NS2B-NS3pro inhibitors, respectively. 
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CHAPTER TWO 
LITERATURE REVIEW 
 
2.1 Influenza A and Its Drug Treatment 
2.1.1 Influenza A virus 
Influenza A virus is a pathogen which commonly infects the upper respiratory 
tract causes several symptoms such as myalgia, malaise, and fever for a few days as 
common respiratory symptoms.  The condition can be more complicated when it 
affects other cells or organs causes pneumonia and myocardial infection (Kuszewski 
and Brydak, 2000; Svetlikova et al., 2010). The major pandemics were reported in 
three periods during 20
th
 centuries: 1918-1921 (H1N1”Spanish” Influenza), 1957-
1958 (H2N2”Asian” Influenza) and 1968 (H3N2”Hongkong”Influenza) (Gautret et 
al., 2010). Since 1997 to 2005, H5N1 influenza became dominant in virus circulation 
among birds but later on, it kills hundreds people worldwide (Saif and Espinoza, 
2006). The swine flu (H1N1) virus was firstly found having human to human 
transmission in Mexico (2009) but luckily, this virus is less pathogenic than H5N1 
virus (Simonsen et al., 2011). The updated status of H1N1 reported by WHO in 2009 
indicated this influenza virus found in 381 human specimens in Washington DC 
(WHO, 2014a). 
 
Influenza A virus is a negative-strand RNA virus belonging to orthomyxo 
viruses. The shape of the virus is a pleomorphic particle, typically having a spherical 
or long „lollypop‟ like filament shape. The enveloped-negative RNA segmented 
genomes are packed into a nucleocapsid which complexes with protein polymerase. 
This RNA-protein (RNPs) complex is packed in a lipoprotein envelope lined by three 
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surface proteins: hemagglutinin (HA), neuraminidase (NA), and the M2 proton ion 
channel (Magano, 2009; Shtyrya et al., 2009).  
 
Figure 2.1 shows the schematic diagramme of Influenza A virus. 
Hemagglutinin (HA) is a glycoprotein which recognizes the cell targets by binding to 
sialic acid receptor on the host cell membrane. This protein binds to the receptor via 
α-ketosidic-linked terminal that are followed by fusion of the viral through the 
endosomal membranes succeeding endocytosis. After endocytosis, the pH of the cell 
changes and triggers the prolongation of the central coiled at the N-terminus thus 
drives out the fusion peptide and penetrates into a cellular membrane (Isin et al., 
2002; Sollner, 2004; von Itzstein, 2007). There are 15 subtypes of HA (H1-H15); 
three of them: H1, H2 and H3 attack humans by binding at the sialic acid receptor in 
the respiratory tract; while another subtype, H5, invades protein in avian digestive 
enzyme (Fouchier et al., 2005). The swine is susceptible toward both human and 
avian influenza virus, thus the novel strain of H1N1can be generated by those two 
virus reassortment in this species leading to the theory called as “mixing vessel” (Ma 
et al., 2007). 
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Figure 2.1 The influenza viral lipid envelope with a nucleocapsid containing three 
surface proteins: hemagglutinin (HA), neuraminidase (NA), and the M2 proton ion 
channel. The genome of the viral RNAs are presented as red coils bound to 
Ribonuclear Proteins (RNPs) (Betakova, 2007). 
 
 
Neuraminidase (NA), also known as sialidase, exists as a tetramer of identical 
subunits. It is normally attached to the virus surface through a long protein stalk. The 
active sites are in a deep depression on the upper surface. They bind to 
polysaccharide chains of the sialic acid receptor and clip off the sugars (sialic acid) at 
the terminal end. The surface of neuraminidase is decorated with several 
polysaccharide chains (seen extending upwards and downwards in this structure, 
Figure 1.1) that are similar to the polysaccharide chains that decorate our own cell 
surface proteins. NA can be divided into 9 subtypes (N1-N9) and it is important for 
viral replication and infection (Du et al., 2007; Tisoncik et al., 2011). This enzyme 
cleaves the terminal sialic acid moieties from the receptors to facilitate release of the 
virion progeny from the infected cell. NA is able to facilitate the early processing of 
influenza virus infection in the lung epithelial cells. Due to these essential roles, NA 
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has been an attractive target in anti-influenza discovery (Du et al., 2007; Gong et al., 
2007; Platis et al., 2006; Wang et al., 2010). 
 
M2 ion protein channel is the third membrane protein which provides the 
virus structural integrity by permitting the proton to enter the virus particle during 
un-coating of the virion in the endosome (Bauer et al., 1999). It is a homotetramer 
consisting of four polypeptide chains from 96 amino acids, with the structural 
domains: an amino-terminal extracellular domain (comprising 23 residues), as a 
single internal hydrophobic domain that acts as a trans-membrane domain (19 
residues) and 54-residue cytoplasmic tails. This membrane protein is important to 
prevent inactivation of progeny virus as well as premature acid activation of the 
newly synthesised HA (Betakova, 2007; Rossman et al., 2010). 
 
2.1.2 Influenza A neuraminidase 
The crystal structure of neuraminidase first solved in 1983 (Varghese et al., 
1983) has given a glimpse on the mechanism of action of this enzyme at a molecular 
level. This structure was of N2 subtype at a resolution of 2.9 Å, showing that the 
enzyme adopts a tetramer shape (see Figure 2.2) with the total molecular weight of 
240 kDa. Each monomer is formed by six 4-stranded of anti-parallel β-sheets which 
is arranged as blade propellers around the central of pseudo six fold. The first strand 
of each sheet is parallel to the central of the propeller and the outer strand is vertical 
toward it, causes each strand being twisted. The outermost strand of the first sheet is 
linked to the central of strand for the next sheets. Loops connecting these strands 
contain a diverse important amino acids and form enzymatic site on its upper surface.  
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Figure 2.2 The tetramer shapes of neuraminidase N2 (Varghese et al., 1983). 
Phylogenetic studies have divided the neuraminidase influenza virus into two 
groups, Group 1 contains subtypes N1, N4, N5 and N8 and Group 2, subtypes N2, 
N3, N6, N7 and N9 (Gong, 2007; Tisdale, 2009). The main difference between these 
two groups is the presence of a loop consisting amino acids 147 to 151 which is also 
named as 150-loop (Xu et al., 2008). For example, the 150-loop of the N1 has 
Val149 while for N9 it is formed by Ile149. For both groups, the 150-loop contains 
an amino acid Asp151 as shown in the superposition of N1 and N9 in Figure 2.3. 
However, in N1, its side chain has a carboxylic acid steering away from the active 
site of the enzyme in an open conformation, while in N9, it is a close form (Du et al., 
2007).  
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Figure 2.3 The comparison of crystal structures between N1 and N9. (A) A 
superposition of N1 (PDBID 2HTY) and N9 enzyme (PDBID 1F8B) where the key 
residues are shown in ball-and-stick forms. (B) Ligand in the active cavity of 2HTY 
with adjacent 150-loop. (C) Ligand  in the active cavity of 1F8B (Du et al., 2007). 
 
 
The function of NA is to facilitate mobility of the virus, both to and from the 
site of infection. NA catalyzes the cleavages of (2-6) - or α (2-3)-ketosidic linkage 
between a terminal SA and inward-face sugar residue. This broken bond facilitates to 
spread the virus in the respiratory tract and allows the elution of progeny virus from 
the infected cells. The removal of sialic acid from the oligosacharide moiety of HA 
and NA also helps to prevent the virus self-aggregation after leaving the host cells 
(Gong et al., 2007). The mechanism of neuraminidase activity that facilitates the 
viral replication is shown in Figure 2.4. 
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Figure 2.4 The cleavage of the new synthesised virus from its sialic acid receptor by 
neuraminidase (Clercq, 2006). 
 
 
The availability of X-ray crystal structures of neuraminidase with high-
resolutions complexed with sialic acid (SA, N-acetylneuraminic acid, Neu5Ac) has 
improved the understanding of the action mechanism of this enzyme. Figure 2.5 
described the active binding site of neuraminidase when co-crystallized with 
Neu5Ac. This active site is highly conserved and presents a rigid catalytic center 
(Gong et al., 2007; von Itzstein, 2007; Yen et al., 2006). There are eight amino acids 
which directly make contact with Neu5Ac which provide conserved binding by the 
charge-charge interaction between the carboxylate group and three positively 
charged arginine residues (Arg118, Arg292 and Arg371). The NH group of 5-N-
Acetyl interacts with the active site cavity via hydrogen bonding with water molecule 
while the oxygen carbonyl on the same 5-N-Acetyl moiety of Neu5Ac bonds to N of 
Arg152 via direct hydrogen bonding while its two hydroxyl groups of glycerol side 
chain are bonded to the carboxylate oxygens of Glu276.  In addition, the 2-hydroxyl 
of Neu5Ac makes a direct contact with the carboxylate oxygen of Asp151 (Varghese, 
1999; von Itzstein, 2007). 
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Figure 2.5 The binding site of A/Tokyo/3/67 (H2N2) influenza virus NA and sialic 
acid (PDBID 2BAT). The green dot lines describe the hydrogen bonding between 
ligand and specific amino acid residues of NA‟s active site (Yen et al., 2006). 
 
 
2.1.3 Neuraminidase Inhibitors 
Most potent NA inhibitors were developed based on the structural 
information of the N2 NA conserved active site and its complex with sialic acid. 
Figure 2.6 shows the two-dimensional „airplane‟ model to illustrate the NA active 
site (Wang et al., 2010). This „airplane‟ model was used to define the Structure-
Activity Relationships (SARs) of NA inhibitors, which is mainly determined by the 
relative positions of the substituents (carboxylate, glycerol, acetamido and hydroxyl) 
in the central ring of the inhibitor. There are four well conserved active site domains 
which consist of Site 1 (Arg118, Arg292, Arg371), Site 2 (Asp151, Glu119, 
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Glu227), Site 3 (Ile222, Trp178) and Site 4 (Glu276, Glu277) (Gong et al., 2007; 
Zhang et al., 2008a).  
 
Figure 2.6 „Airplane‟ model of NA active site (Zhang et al., 2008a). 
 
The elucidation of the three-dimensional structure of influenza neuraminidase 
located the catalytic site, which makes the design of highly effective inhibitors 
became feasible. The first NA inhibitor is 2-deoxy-2,3-didehydro-N-
acetylneuraminic acid (DANA (1), Figure 2.7) synthesised in 1969 (Chen et al., 
2013). It was designed as a mechanism-based inhibitor and was proposed to be a 
transition state analogue with Ki ~1pM.  Compound 1 showed a good activity in vitro 
but was found inactive as antivirals in an animal model (Laver and Elspeth, 2002).  
Earlier structure based drug design work, showed the availability of space between 1 
and the enzyme in the vicinity of the 4-hydroxyl binding pocket, and thus, it was 
desirable to fill that space with basic substituents on the sugar (Smith et al., 2001). 
Upon this information, the compounds targeted for synthesis were 4-amino-
Neu5Ac2en (2) and 4-guanidino-Neu5Ac2en (3) (Figure 2.7). The Ki of these 
compounds are 20 and 5000 times respectively improved over that for 1 when 
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assayed against the neuraminidase of the viral isolate from which the structure had 
been determined. 
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Figure 2.7 The structure of NA inhibitors from sialic acid derivatives (Tapar et al., 
2011). 
 
 
Compound 3 or its drug name Zanamivir has an oral inhalation administration 
not only due to its high polarity, but also consciously intended for direct delivery to 
the respiratory tract, the principal site of the viral replication (Gupta et al., 2011; Sun 
et al., 2010). This sialic acid derivative showed a potent antiviral activity in vitro 
against influenza A as well as B viruses, including amantadine-and rimantadine-
resistant isolates. Further study also showed that 3 is active against avian influenza A 
viruses, including influenza A H5N1, H6N1, H7N7 and H9N2 as well as some 
influenza strains resistant to oseltamivir (Elliot, 2001).  
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A new orally active neuraminidase inhibitor, coded by GS4071 (4) was 
designed to overcome the problem of oral bioavailability of zanamivir (Zhang et al., 
1997). The decrease in polarity contributed by carboxyl, hydroxyl as well as 
guanidine in zanamivir was achieved in 4 by removing the heterocyclic oxygen but 
augmenting the isopentyl as shown in Figure 2.8. 
 
Figure 2.8 The structure of 4 with the dot boxes describes the nonpolar site of the 
particular structure. 
 
 
The similarity of this compound to the compound 2 is evident especially their 
binding mode as demonstrated from the X-ray crystal structure of the complexes 
bound to neuraminidase (Figure 2.9). The carboxylate, acetyl as well as amino group 
belongs to the compound 4 were shown to bind to the conserved amino acid residues 
of neuraminidase‟s active site. In addition, the isopentyl group makes several 
favorable hydrophobic contacts with amino acid residues Ile222, Arg224, and 
Ala246, increasing the binding affinity (Lew et al., 2000).  
22 
 
Figure 2.9 The X-ray crystal structure of neuraminidase complex with 4. The 
hydrophobic interactions are indicated by the closeness between isopentyl group and 
amino acid residues Ile222, Arg224 and Ala246 (Lew et al., 2000). 
 
 
In pharmacokinetic experiments, 4 demonstrated only ~5% bioavailability in 
rats which is similar to 3. Somehow, the conversion of carboxylic acid to its ester 
form, oseltamivir, provides five folds higher bioavailability than 4 when it is 
administered orally. It was found that the ethyl ester form of this compound 
metabolized via hydrolysis reaction to become carboxylate, the active metabolite 
which is shown to have poor bioavailability. Therefore, the phosphate salt of 
oseltamivir was developed to overcome the bioavailability problem thus, the 
compound can be administered orally (D'Souza et al., 2009; Sun et al., 2010).  
 
The recent X-ray crystallographic study reveals that influenza A virus of the 
group-1 NA (N1) contains a larger cavity adjacent to the active site, formed by 
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residue 147-152 (150-loop) which is not found in the group 2 NAs. The group 1 NAs 
can bind ligands in the open as well as in the closed conformation. However, only the 
close conformational state was found in the group 2 NAs. The flexible 150-loop 
residues are occupied on the vicinity by the ligand and interact mostly with the 
amino and acetamido groups of 4. The active sites are still conserved at the triad 
arginines (Arg118, Arg292, and Arg371) that interact with the carboxylate group. 
Moreover, the affinity is increased by the interaction between the acetamido group 
and Glu276 that forms hydrogen bonds with the substrate of hydroxyl groups 
(Collins et al., 2008; Rungrotmongkol et al., 2009).  
 
A new scaffold containing five members of alicyclic compound was 
introduced to generate the antiviral activity against influenza virus via neuraminidase 
inhibition (Bianco et al., 2005). Peramivir (5) with the cyclopentane core attached 
with carboxylic acid as well as acetylamino group and showed to possess in vitro 
activity against H1N1 virus with IC50 = 0.38 M (Ikematsu et al., 2012). The crystal 
structure of N8 complex with Peramivir (PDBID 2HTU) shows the conserved 
binding mode of this compound to the enzyme (see Figure 2.10).  
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Figure 2.10 The structure of 5 in 2D as well as its 3D structure complex to N8 NA 
(PDBID 2HTU) was generated using Discovery Studio 2.5. 
 
The latest NA inhibitor clinically approved in Japan in 2010 is Laninamivir 
which is proven effective against oseltamivir-resistant mutant. This drug is also 
prepared in octanoate ester form in the major structure of 3. This laninamivir ester 
(6) is unique in its ability to rotate the Glu276 to form a salt bridge with Arg224, thus 
giving more space for Asn294 to interact with the the 9-ester-O of Laninamivir when 
it was crystallized with 2009 H1N1 NA (p09N1) (see Figure 2.11) (Ikematsu and 
Kawai, 2011; Vavricka et al., 2011).  
